Jason J. Luke
Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma.
Overview
Jason Luke was principal investigator of KEYNOTE-716, which showed adjuvant pembrolizumab reduces recurrence and distant metastasis in resected stage IIB and IIC melanoma, the first adjuvant immunotherapy approval in stage II disease. He runs one of the largest early-phase immunotherapy programmes in the United States and studies mechanisms of primary resistance to checkpoint blockade. He is active in SITC leadership.
| Title | Journal | Year |
|---|---|---|
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716) | Lancet | 2022 |
| Targeted agents and immunotherapies: optimizing outcomes in melanoma | Nature Reviews Clinical Oncology | 2017 |
Pages like this
not linked directly; found by shared links- PersonSapna P. Patel
Shares Nature Reviews Clinical Oncology, Pembrolizumab, PD-1, Melanoma and the tag melanoma.
- PersonJeffrey S. Weber
Shares Pembrolizumab, PD-1, Melanoma, Immune checkpoint inhibitors and the tags melanoma, adjuvant.
- PersonCaroline Robert
Shares Pembrolizumab, PD-1, Melanoma, Immune checkpoint inhibitors and the tag melanoma.
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares KEYNOTE-716, Melanoma, Immune checkpoint inhibitors.
- PersonMichael A. Postow
Shares PD-1, Melanoma, Immune checkpoint inhibitors and the tag melanoma.
- PersonJedd D. Wolchok
Shares PD-1, Melanoma, Immune checkpoint inhibitors and the tag melanoma.
- PersonThierry André
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag adjuvant.
- TrialKEYNOTE-006
Shares Pembrolizumab, PD-1, Melanoma, Immune checkpoint inhibitors.